Kéforal

Cefalexin Monohydrate, the active ingredient in Kéforal, is a first‑generation cephalosporin presented as an oral tablet for systemic use. It treats a range of bacterial infections in adults and children, including skin, respiratory and urinary tract infections.

GNH USA supplies Kéforal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Cefalexin Monohydrate is a broad‑spectrum cephalosporin antibiotic used to treat infections caused by susceptible bacteria. - Skin and soft‑tissue infections: resolves cellulitis, impetigo and wound infections. - Respiratory tract infections: treats acute bronchitis, sinusitis and community‑acquired pneumonia. - Urinary tract infections: eradicates uncomplicated cystitis and pyelonephritis. - Bone and joint infections: aids in osteomyelitis and septic arthritis management. - Otitis media: clears middle‑ear bacterial infection in children and adults.

Adverse reactions may occur with any antibiotic therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: often self‑limited, may be watery. - Abdominal pain: cramping or discomfort. - Rash: erythematous skin eruption. - Headache: transient tension‑type pain. - Vaginal candidiasis: overgrowth due to altered flora.

Serious or Rare Side Effects: - Clostridioides difficile‑associated colitis: severe watery diarrhea. - Anaphylaxis: rapid onset of hives, airway swelling, hypotension. - Stevens‑Johnson syndrome: painful skin blistering and mucosal involvement. - Hematologic abnormalities: neutropenia, eosinophilia, thrombocytopenia. - Hepatic dysfunction: elevated transaminases or jaundice. - Renal impairment: interstitial nephritis or worsening kidney function.

Before prescribing Cefalexin Monohydrate, clinicians should consider patient‑specific factors and safety measures. - Allergy assessment: verify no known hypersensitivity to penicillins or cephalosporins. - Renal function: adjust dose in patients with impaired clearance. - Hepatic impairment: use with caution in liver disease. - Elderly patients: monitor for increased adverse effects due to altered pharmacokinetics. - Concomitant antibiotics: avoid unnecessary combination therapy to reduce resistance risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Cefalexin Monohydrate can alter the activity of several co‑administered medicines.

Major Interactions (Avoid): - Probenecid: reduces renal excretion, increasing cefalexin plasma levels. - Warfarin: may enhance anticoagulant effect, raising INR. - Oral contraceptives: possible reduction in contraceptive efficacy. - Aminoglycosides: combined nephrotoxicity risk. - Live bacterial vaccines: decreased vaccine effectiveness.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: decrease cefalexin absorption. - Diuretics (e.g., furosemide): may affect renal clearance. - Metformin: monitor for altered renal elimination. - Allopurinol: rare reports of rash when combined.